TR201908367T4 - Anti̇korlar ve endogsi̇kozi̇tleri̇n bi̇rleşti̇ri̇lmi̇ş terapeuti̇k kullanimi - Google Patents
Anti̇korlar ve endogsi̇kozi̇tleri̇n bi̇rleşti̇ri̇lmi̇ş terapeuti̇k kullanimi Download PDFInfo
- Publication number
- TR201908367T4 TR201908367T4 TR2019/08367T TR201908367T TR201908367T4 TR 201908367 T4 TR201908367 T4 TR 201908367T4 TR 2019/08367 T TR2019/08367 T TR 2019/08367T TR 201908367 T TR201908367 T TR 201908367T TR 201908367 T4 TR201908367 T4 TR 201908367T4
- Authority
- TR
- Turkey
- Prior art keywords
- antibody
- agent
- antibodies
- endogsycosids
- therapeutic use
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 102000009109 Fc receptors Human genes 0.000 abstract 1
- 108010087819 Fc receptors Proteins 0.000 abstract 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 abstract 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000007515 enzymatic degradation Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Bir hastalığın bir tedavi yönteminde kullanılması için endojen serum antikorlarının enzimatik degradasyonu ile Fc reseptör bağlanımını azaltan bir ajan olup, özelliği; ajanın bir endoglikosidaz, bir proteaz ya da bir protein-N-glikanaz olmasıdır ve bir antikorun terapötik potensini arttıran bir yöntem olup, özelliği; bahsi geçen antikorun etki şeklinin, Fc: FcR etkileşimine dayanmasıdır ve özelliği; yöntemin aşağıdaki adımları kapsamasıdır: (a) bahsi geçen ajanın bir deneğe tatbik edilmesi; ve akabinde, (b) belirlenen bir zaman aralığı sonrasında, bahsi geçen antikorun deneğe tatbik edilmesi.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201201314A GB201201314D0 (en) | 2012-01-26 | 2012-01-26 | Composition |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201908367T4 true TR201908367T4 (tr) | 2019-06-21 |
Family
ID=45840985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/08367T TR201908367T4 (tr) | 2012-01-26 | 2013-01-25 | Anti̇korlar ve endogsi̇kozi̇tleri̇n bi̇rleşti̇ri̇lmi̇ş terapeuti̇k kullanimi |
Country Status (17)
Country | Link |
---|---|
US (4) | US20150125443A1 (tr) |
EP (1) | EP2806892B1 (tr) |
JP (1) | JP6249962B2 (tr) |
CN (2) | CN108619509A (tr) |
CY (1) | CY1122060T1 (tr) |
DK (1) | DK2806892T3 (tr) |
ES (1) | ES2728290T3 (tr) |
GB (1) | GB201201314D0 (tr) |
HR (1) | HRP20191022T1 (tr) |
HU (1) | HUE044632T2 (tr) |
IN (1) | IN2014DN06722A (tr) |
LT (1) | LT2806892T (tr) |
PL (1) | PL2806892T3 (tr) |
PT (1) | PT2806892T (tr) |
SI (1) | SI2806892T1 (tr) |
TR (1) | TR201908367T4 (tr) |
WO (1) | WO2013110946A1 (tr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
JP6486368B2 (ja) | 2013-09-06 | 2019-03-20 | アカデミア シニカAcademia Sinica | 改変されたグリコシル基を含む糖脂質を用いたヒトiNKT細胞の活性化 |
GB201318490D0 (en) * | 2013-10-18 | 2013-12-04 | Genovis Ab | Method |
JP2017518989A (ja) | 2014-05-27 | 2017-07-13 | アカデミア シニカAcademia Sinica | 抗cd20糖操作抗体群およびその使用 |
CN107074945B (zh) * | 2014-05-27 | 2021-08-24 | 中央研究院 | 增进抗体功效的通用糖型的组合物及方法 |
TWI679020B (zh) | 2014-05-27 | 2019-12-11 | 中央研究院 | 抗her2醣抗體及其用途 |
TWI732738B (zh) | 2014-05-28 | 2021-07-11 | 中央研究院 | 抗TNF-α醣抗體及其用途 |
GB201413240D0 (en) * | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
TWI730972B (zh) * | 2015-07-16 | 2021-06-21 | 日商第一三共股份有限公司 | 新穎EndoS變異酵素及使用其之經糖鏈重塑之含Fc區域的分子之製造方法 |
BR112018015259A2 (pt) * | 2016-01-27 | 2018-12-18 | Medimmune Llc | métodos para preparação de anticorpos com um padrão de glicosilação definido |
US10434141B2 (en) | 2016-05-31 | 2019-10-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
JP2017226648A (ja) * | 2016-06-17 | 2017-12-28 | SonoCore株式会社 | 分子標的薬バブルおよび分子標的薬バブルの製造方法 |
US20210228738A1 (en) * | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
CN110151987B (zh) * | 2018-02-11 | 2023-10-13 | 汕头大学医学院 | 对称IgG及其组合物在制备治疗及预防肿瘤的药物中的用途 |
US20230049145A1 (en) * | 2019-12-12 | 2023-02-16 | Fresenius Kabi Deutschland Gmbh | Glycosylated polypeptides |
GB202007431D0 (en) | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Cysteine protease |
CN115066261A (zh) * | 2020-06-05 | 2022-09-16 | 上海宝济药业有限公司 | 一种酶和病毒的药物组合及其应用 |
CN113769058A (zh) * | 2020-06-10 | 2021-12-10 | 上海宝济药业有限公司 | 一种药物组合及其应用 |
WO2022057942A1 (zh) * | 2020-09-21 | 2022-03-24 | 上海宝济药业有限公司 | 一种药物组合及其应用 |
JPWO2022124096A1 (tr) * | 2020-12-11 | 2022-06-16 | ||
EP4079848A1 (en) | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US20040136986A1 (en) | 1997-10-31 | 2004-07-15 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
GB0130228D0 (en) | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
EP2319935B1 (en) | 2002-03-19 | 2016-04-27 | Stichting Dienst Landbouwkundig Onderzoek | GnTIII (UDP-N-acetylglucosamine:Beta -D mannoside Beta (1,4)-N-acetylglucosaminyltransferase III) expression in plants. |
ES2282673T3 (es) | 2002-07-15 | 2007-10-16 | Janssen Pharmaceutica N.V. | Analogos 3-furanilo de toxoflavina como inhibidores de quinasas. |
GB0624874D0 (en) * | 2006-12-13 | 2007-01-24 | Hansa Medical Ab | Treatment |
WO2009033670A2 (en) * | 2007-09-14 | 2009-03-19 | Genovis Ab | Method and kits for dissociating fcgamma-receptor-igg complexes and for igg purification and detection |
CN107074945B (zh) * | 2014-05-27 | 2021-08-24 | 中央研究院 | 增进抗体功效的通用糖型的组合物及方法 |
-
2012
- 2012-01-26 GB GB201201314A patent/GB201201314D0/en not_active Ceased
-
2013
- 2013-01-25 DK DK13701871.9T patent/DK2806892T3/da active
- 2013-01-25 ES ES13701871T patent/ES2728290T3/es active Active
- 2013-01-25 PL PL13701871T patent/PL2806892T3/pl unknown
- 2013-01-25 CN CN201810607247.8A patent/CN108619509A/zh active Pending
- 2013-01-25 PT PT13701871T patent/PT2806892T/pt unknown
- 2013-01-25 LT LTEP13701871.9T patent/LT2806892T/lt unknown
- 2013-01-25 SI SI201331476T patent/SI2806892T1/sl unknown
- 2013-01-25 US US14/374,612 patent/US20150125443A1/en not_active Abandoned
- 2013-01-25 TR TR2019/08367T patent/TR201908367T4/tr unknown
- 2013-01-25 JP JP2014553802A patent/JP6249962B2/ja active Active
- 2013-01-25 CN CN201380012248.3A patent/CN104519911B/zh active Active
- 2013-01-25 HU HUE13701871 patent/HUE044632T2/hu unknown
- 2013-01-25 WO PCT/GB2013/050164 patent/WO2013110946A1/en active Application Filing
- 2013-01-25 EP EP13701871.9A patent/EP2806892B1/en active Active
-
2014
- 2014-08-11 IN IN6722DEN2014 patent/IN2014DN06722A/en unknown
-
2017
- 2017-03-02 US US15/447,622 patent/US20170274070A1/en not_active Abandoned
-
2019
- 2019-06-06 HR HRP20191022TT patent/HRP20191022T1/hr unknown
- 2019-06-06 CY CY20191100598T patent/CY1122060T1/el unknown
-
2020
- 2020-07-17 US US16/932,588 patent/US20200345844A1/en not_active Abandoned
-
2023
- 2023-08-21 US US18/453,107 patent/US20230398212A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN104519911B (zh) | 2018-07-17 |
US20170274070A1 (en) | 2017-09-28 |
CY1122060T1 (el) | 2020-11-25 |
LT2806892T (lt) | 2019-07-25 |
US20200345844A1 (en) | 2020-11-05 |
US20150125443A1 (en) | 2015-05-07 |
IN2014DN06722A (tr) | 2015-05-22 |
SI2806892T1 (sl) | 2019-08-30 |
WO2013110946A1 (en) | 2013-08-01 |
DK2806892T3 (da) | 2019-06-11 |
JP6249962B2 (ja) | 2017-12-20 |
US20230398212A1 (en) | 2023-12-14 |
PT2806892T (pt) | 2019-06-17 |
ES2728290T3 (es) | 2019-10-23 |
EP2806892A1 (en) | 2014-12-03 |
HRP20191022T1 (hr) | 2019-09-06 |
GB201201314D0 (en) | 2012-03-07 |
CN104519911A (zh) | 2015-04-15 |
CN108619509A (zh) | 2018-10-09 |
HUE044632T2 (hu) | 2019-11-28 |
EP2806892B1 (en) | 2019-03-06 |
JP2015511223A (ja) | 2015-04-16 |
PL2806892T3 (pl) | 2019-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201908367T4 (tr) | Anti̇korlar ve endogsi̇kozi̇tleri̇n bi̇rleşti̇ri̇lmi̇ş terapeuti̇k kullanimi | |
EA201592269A1 (ru) | Способы и композиции для снижения иммуносупрессии опухолевыми клетками | |
MX2021002728A (es) | Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores. | |
NI201700001A (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
EA201290590A1 (ru) | Модифицированные туберкулезные антигены | |
EA201491006A1 (ru) | Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo | |
TN2015000050A1 (en) | Methods of treating a tauopathy | |
EA201300239A1 (ru) | Антитела к fap и способы их применения | |
BR112015000657A8 (pt) | uso de uma célula geneticamente modificada para expressar um car. | |
MX358224B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado. | |
EA201500219A1 (ru) | Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo | |
MX2018013128A (es) | Molecula de union al antigeno para promover la perdia de antigeno a traves de fc gamma riib. | |
EA201490636A1 (ru) | Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований | |
TR201819812T4 (tr) | Kanserin Tedavisi Ve/Veya Önlenmesi Amacına Yönelik Farmasötik Bileşim | |
EA201400579A1 (ru) | Антитела к il-36r | |
EA201790192A1 (ru) | СПОСОБ СНИЖЕНИЯ Fc-РЕЦЕПТОРНОГО СВЯЗЫВАНИЯ МОЛЕКУЛ СЫВОРОТОЧНОГО IgG У СУБЪЕКТА | |
UA116772C2 (uk) | Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47 | |
TR201905909T4 (tr) | Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları. | |
NZ623086A (en) | Therapeutic peptides | |
TN2014000120A1 (en) | Cd27l antigen binding proteins | |
MX2015007147A (es) | Metodo de reduccion de placas amiloides de cerebro que usan anticuerpos anti-ab. | |
TR201904980T4 (tr) | Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar. | |
EA201390940A1 (ru) | Материалы и способы конъюгирования водорастворимого производного жирной кислоты с белком | |
WO2012064792A3 (en) | Protein complexes for antigen binding and methods of use | |
EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека |